|Bid||309.51 x 800|
|Ask||309.61 x 800|
|Day's range||304.70 - 311.99|
|52-week range||222.65 - 358.07|
|Beta (5Y monthly)||1.31|
|PE ratio (TTM)||72.63|
|Earnings date||22 Jan 2024 - 26 Jan 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||329.19|
In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $310.76, denoting a -0.06% change from the preceding trading day.
Intuitive Surgical, Inc. (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
It's a bit of a harrowing time to be in the business of selling solutions for bariatric surgery. Thanks to Novo Nordisk's drugs like Ozempic and Wegovy for type 2 diabetes and obesity, and competing medicines like Mounjaro and Zepbound made by Eli Lilly, people now have access to powerful and noninvasive weight-loss tools. In fact, leaders of two of the largest companies in healthcare, Intuitive Surgical (NASDAQ: ISRG) and Johnson & Johnson (NYSE: JNJ), are already explicitly linking the rise of treatments like Ozempic to new headwinds for certain segments of their businesses.